Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
Phase III trial investigates treatment noninferiority of THP versus TCbHP in HER2-positive breast cancer, suggesting carboplatin omission may be viable.
Key Points
The aim was to assess the efficacy and safety of THP compared to TCbHP in HER2-positive breast cancer.
Randomized multicenter phase III study
Women aged 18 or older with untreated stage II and III HER2-positive breast cancer
Patients received six 3-week cycles of TCbHP or THP
Primary endpoint was pathologic complete response (pCR) rate
pCR achieved in 64.1% of the THP group and 65.9% of the TCbHP group
THP had fewer grade 3 and 4 adverse events (20.7% vs 34.6%)
Serious adverse events were 1.3% in THP vs 4.7% in TCbHP